Form 4: Dexcom Executive Sells Shares Under Pre-Arranged 10b5-1 Plan

Dexcom's EVP, Chief HR Officer, Sadie Stern, sold 1,466 shares of common stock for $85.06 per share on June 26, 2025, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Sadie Stern, Dexcom Inc.'s EVP, Chief HR Officer, sold 1,466 shares of DXCM common stock.
• The transaction occurred on June 26, 2025, at a price of $85.06 per share, totaling approximately $124,707.96.
• The sale was executed under a Rule 10b5-1 trading plan adopted by Ms. Stern on February 20, 2025, designed for the orderly disposition of shares.
• Following this transaction, Ms. Stern directly beneficially owns 108,155 shares of common stock.
• This beneficial ownership includes 74,450 unvested restricted stock units (RSUs).
• The unvested RSUs include 29,922 units granted on March 8, 2025, vesting through March 8, 2028; 22,798 units granted on March 8, 2025, vesting through March 8, 2027; 14,474 units granted on March 8, 2024, vesting through March 8, 2027; and 7,256 units granted on March 8, 2023, vesting through March 8, 2026.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transaction is a routine insider sale under a pre-arranged 10b5-1 plan, which is a common practice for executives to manage their equity holdings and does not inherently signal positive or negative company performance.

Positives

• The sale was conducted under a Rule 10b5-1 plan, indicating a pre-planned and orderly disposition of shares rather than a reactive sale.
• The reporting person retains a significant beneficial ownership of 108,155 shares, including a substantial number of unvested restricted stock units, aligning her interests with long-term company performance.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by investors as it reduces the insider's direct equity stake.

Future Outlook

N/A

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide broader industry context or trends. It reflects an individual executive's pre-planned equity management.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale is a routine insider transaction under a 10b5-1 plan, which typically has minimal direct impact on share price or shareholder value, as it's a pre-planned disposition rather than a reactive one.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Key Dates

Keywords

Dexcom, DXCM, Sadie Stern, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Restricted Stock Units, Executive Compensation, SEC Filing